ArticleFrontiers in endocrinology2026
Metabolic dysfunction-associated steatotic liver disease and bone mineral density in type 2 diabetes mellitus: insights from a single-center cross-sectional study in North India.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), recently redefined from non-alcoholic fatty liver disease, commonly coexists with type 2 diabetes mellitus and may adversely affect skeletal health through inflammation and insulin resistance. However, research on site-specific bone mineral density (BMD) effects in South Asian populations, particularly Indians, remains limited. This study aimed to evaluate the association between MASLD and BMD at different skeletal sites among adults with type 2 diabetes mellitus in North India. Methods: This cross-sectional study included 100 adults (50 with T2DM and 50 controls) at a tertiary care center in Jaipur, India. MASLD was evaluated using the fibrosis-4 (FIB-4) index, hepato-renal index, and two-dimensional shear wave elastography. BMD at lumbar spine (L1-L4), left total hip (proximal femur), and left forearm was assessed by dual-energy X-ray absorptiometry. Associations between MASLD parameters and BMD were analyzed using multivariable linear regression, adjusting for age, sex, and smoking status. Results: T2DM patients showed significantly lower lumbar spine (L1-L4) BMD (0.93 vs. 0.98 g/cm Conclusion: This study establishes significant, site-specific associations between MASLD and reduced bone mineral density in type 2 diabetes mellitus patients, particularly affecting trabecular-rich skeletal sites. The complex relationship between hepatic steatosis and skeletal health highlights the multisystemic nature of metabolic dysfunction. These findings support integrating bone health assessments and non-invasive hepatic fibrosis screening into routine diabetes care to improve early risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.